Meda is primarily active in late stage clinical development and the development function has 449 employees who work on development, clinical trials and drug registration.
The value-generating work performed in Meda’s development department is focused on tailored clinical development programs and the compilation of scientific arguments defending, exploring and highlighting product features. As a specialty pharma company, Meda refrains from high-risk, capital-intensive early research. Instead the company’s resources are concentrated on development ‘close to market’ in the late clinical or registration phases. The focus is often on well-known active ingredients and improving the characteristics of existing products, for example through:
• New improved formulations, such as a pen in addition to the cotton swab for the medical device product EndWarts, which contains formic acid for the treatment of warts
• Development of combination products, such as Dymista (azelastine and fluticasonepropionate) for allergic rhinitis
• Internationalization and regulatory approval of approved drugs, such as Novolizer, Acnatac, Zyclara and Dymista, in new countries/ regions